WEBINAR—Organ Chips in Translational Physiology Research: From Discovery to Clinical Study Design

January 22
1 p.m. EST

Passley Hargrove-Grimes, PhD, of the National Center for Advancing Translational Sciences (NCATS), will discuss the “Clinical Trials on a Chip” initiative and the utility of tissue chip technology to cross-validate disease model endpoints, establish recruitment criteria and stratify patient populations.  

Gautam Mahajan, PhD, of Emulate Bio, will introduce the core principles and mechanisms of organ-on-a-Chip technology and its applications to neuroscience research, including tissue interfaces, physiological flow and multicellular interactions to improve translational relevance beyond traditional static models. Mahajan will then present an in-depth overview of Emulate’s Brain-Chip R1, a first-in-class, isogenic five-cell iPSC model of the human neurovasculature. 

Dmitriy Krepkiy, PhD, of NCATS, will showcase research from the Tissue Chips in Space program, which uses tissue chips on the International Space Station to study the effects of microgravity on the human body. The research focuses on how microgravity exerts a unique range of stresses and pathophysiological perturbations on human-derived cells and tissues. 

Speakers 

Passley Hargrove-Grimes, PhD  
Program Officer, National Institutes of Health (NIH) National Center for Advancing Translational Sciences Office of Special Initiatives

Passley Hargrove-Grimes, PhD, is a program officer at the National Institutes of Health (NIH) National Center for Advancing Translational Sciences Office of Special Initiatives. She oversees a dynamic portfolio within the NIH Tissue Chips for Drug Screening Program and manages the “Clinical Trials on-a-Chip” and “Translational Centers for Microphysiological Systems Initiatives.”  

Gautam Mahajan, PhD  
Principal Scientific Lead, Emulate Bio

Gautam Mahajan, PhD, is principal scientific lead at Emulate Bio. driving adoption of organ-on-a-chip technology and leading external research and innovation projects with regulatory agencies such as the Food and Drug Administration. He has authored peer-reviewed publications in complex in vitro technologies. Mahajan earned his PhD in biomedical engineering from Cleveland State University and Cleveland Clinic. He completed a postdoctoral fellowship in The lab of Donald Ingber, MD, PhD, at the Wyss Institute at Harvard University. Mahajan’s research led to the development of clinically relevant organ-on-a-chip models of the human vagina and lymph node to evaluate efficacy and toxicity of drug candidates, probiotics and adjuvants.  

Dmitriy Krepkiy, PhD 
Program Officer, National Center for Advancing Translational Sciences Office of Special Initiatives

Dmitriy Krepkiy, PhD, is a program officer in the National Center for Advancing Translational Sciences Office of Special Initiatives. He oversees the NIH-wide Tissue Chip for Drug Screening program, where he serves as a liaison between funded investigators, NIH administrative and program management staff, and external collaborators. Krepkiy earned his PhD in chemistry from the University of Wisconsin-Milwaukee.  

Marc Ferrer, PhD
Acting Branch Chief, Early Translational Branch and Director, 3D Tissue Bioprinting Laboratory, National Center for Advancing Translational Sciences, National Institutes of Health

Marc Ferrer, PhD, is the acting branch chief of the Early Translational Branch and director of the 3D Tissue Bioprinting Laboratory at the National Center for Advancing Translational Sciences at the National Institutes of Health. His research uses 3D bioengineered tissues for disease modeling and as predictive assay platforms for drug discovery and development. Ferrer graduated with a BSc in organic chemistry from the University of Barcelona, Spain, and received his PhD in biological chemistry from the University of Minnesota. 

Sponsor